Accessibility/Mobile Features
Skip Navigation
Skip to Content
Editorial News
Business
Classified Sites

The Canadian Press - ONLINE EDITION

Pfizer launches nonprescription version of top-selling heartburn treatment, Nexium 24HR

TRENTON, N.J. - A nonprescription version of Nexium, the most popular medicine for frequent, severe heartburn, has just gone on sale.

Drugmaker Pfizer Inc. said Tuesday that over-the-counter Nexium 24HR is available for online orders at www.Nexium24HR.com and will be in most retailers nationwide within three days.

The nonprescription version is a 20-milligram dose of "the purple pill," known chemically as esomeprazole.

Patients are to take one pill daily for up to 14 days, so it's sold in packages of 14, 28 or 42 pills, priced at about $15 to $30. Prescription Nexium, which will still be available in 20- and 40-milligram strengths, costs $260 a month or more, without insurance coverage.

New York-based Pfizer said it's planning consumer ads about the launch, which it's begun promoting at www.facebook.com/Nexium24HR . Pfizer also is offering $1-off coupons for it on the website and www.coupons.com .

In 2012, Pfizer acquired exclusive worldwide rights to nonprescription Nexium from maker AstraZeneca PLC. The British drugmaker got a payment of $250 million and will receive royalties and other payments based on the level of sales.

AstraZeneca will manufacture the nonprescription version for Pfizer and continue selling prescription Nexium, which can take one to four days for full effect. It's heavily advertised as "the purple pill that can provide 24-hour relief from persistent heartburn" caused by acid reflux disease. Unlike antacids, Nexium blocks the "pumps" that release acid into the stomach.

The Food and Drug Administration approved over-the-counter Nexium 24HR two months ago.

Last year, Nexium was the sixth-bestselling prescription drug in the world, generating revenue of $7.86 billion, up 7 per cent from 2012 sales, according to health data firm IMS Health. Competition from the nonprescription version likely will reduce sales in the future.

Over the past month, Pfizer repeatedly courted AstraZeneca, offering as much as $119 billion to buy the company in what would have been the biggest pharmaceutical acquisition ever. After repeated rebuffs, Pfizer ended its pursuit Monday.

___

Follow Linda A. Johnson at www.twitter.com/LindaJ_onPharma

  • Rate this Rate This Star Icon
  • This article has not yet been rated.
  • We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high. If you thought it was well written, do the same. If it doesn’t meet your standards, mark it accordingly.

    You can also register and/or login to the site and join the conversation by leaving a comment.

    Rate it yourself by rolling over the stars and clicking when you reach your desired rating. We want you to tell us what you think of our articles. If the story moves you, compels you to act or tells you something you didn’t know, mark it high.

Sort by: Newest to Oldest | Oldest to Newest | Most Popular 0 Commentscomment icon

You can comment on most stories on brandonsun.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

There are no comments at the moment. Be the first to post a comment below.

Post Your Commentcomment icon

Comment
  • You have characters left

The Brandon Sun does not necessarily endorse any of the views posted. Comments are moderated before publication. By submitting your comment, you agree to our Terms and Conditions. New to commenting? Check out our Frequently Asked Questions.

letters

Make text: Larger | Smaller

Brandon Sun Business Directory
The First World War at 100
Why Not Minot?
Welcome to Winnipeg

Social Media

Canadian Mortgage Rates